The Future of Biotech and Medtech

Join us for a panel discussion with distinguished local alumni on the future of biotech and medtech.

$30/person for general admission 
$20/person for recent graduates (graduated after 2004) 

Online registration has now closed. Tickets will also be available at the door.
Tickets include panel discussion and networking reception with beer, wine, and appetizers. 

Please join us for an evening panel discussion on “The Future of Biotech and Medtech”, hosted by the University of Chicago Alumni Club of San Diego. Hear about exciting innovations, cutting edge research on the use of genomic sequencing to combat aging, FDA regulatory issues, and business challenges in the biotech/medtech field.

5:30 - 6:30 p.m. - Networking reception
6:30 - 7:30 p.m. - Introductions, presentations and panel discussion
7:30 - 8:00 p.m. - Audience Q&A 


Marcelo Lima, MBA ‘88
Founder, President and CEO, ImThera Medical, Inc.

ImThera has developed a novel neurostimulation medical device to treat obstructive sleep apnea [OSA] and is in process of obtaining FDA IDE clearance for its Pivotal study. Mr. Lima has more than 30 years of experience in the medical industry, holding positions in engineering, marketing, business development, and general executive management. Previously, he has been President of Visage Imaging and CEO of Opsion Medical, held leadership positions at Kodak Health Imaging, Hewlett Packard Medical Products Group, Siemens Medical and Johnson & Johnson. Mr. Lima holds a Master of Business Administration degree from the University of Chicago, a Master of Science degree in biomedical engineering from Boston University, and a Bachelor of Science degree in electrical engineering from Gama Filho University (UGF) in Brazil.

Dan Maneval, UC Parent ‘17
Vice President, Pharmacology and Safety Assessment
Halozyme Therapeutics, Inc.

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products based on enzymes that target the extracellular matrix. The Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. PEGPH20, a pegylated hyaluronidase, is an investigational new molecular entity administered intravenously that targets the external environment of solid tumors. Phase 2 clinical studies with PEGPH20 are underway in patients with pancreatic cancer.

Dan is a scientific leader with 20 years of experience in both small biotechnology and large pharmaceutical organizations. As a scientist at Genentech Inc., Dan participated in the preclinical and early clinical development of Herceptin® (trastuzumab), a successful biopharmaceutical used for the treatment of women with breast cancer. At Schering-Plough/Canji, he held various positions of increasing responsibility and worked with a dedicated team of investigators to advance novel gene-based therapeutics into clinical testing. Dan’s field of expertise is in preclinical pharmacology, pharmacokinetics, and early-phase clinical investigation of novel biologics. Dan has a B.S., Biomedical Engineering and PhD, Biomedical Engineering from University of Southern California and completed post-doctoral work at St. Jude Children’s Research Hospital. Dan also serves on the West Coast Advisory Committee for Boston University College of Engineering.

Yaron Turpaz, PhD, MBA ‘12
Chief Information Officer
Human Longevity, Inc.

Human Longevity Inc. (HLI) is a Craig Venter-backed genomics and cell therapy-based diagnostic and therapeutic company. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world’s most comprehensive database to tackle the diseases associated with aging-related human biological decline. HLI is also leading the development of cell-based therapeutics to address age-related decline in endogenous stem cell function. HLI is concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia.

In his role as CIO at HLI, Turpaz is responsible for building and growing the company’s genomic and phenotypic database business, and leads all bioinformatics/informatics and software engineering efforts. Turpaz was previously at AstraZeneca where he was the Vice President, R&D IT responsible for the global IT organization services, analytics and infrastructure supporting drug discovery and development. In this position he led a global team of approximately 300 and was accountable for the more than $120 million R&D IT budget. In 2011 he started at the company as the Vice President of Informatics and Information Sciences. He led a global team who were responsible for developing Big Data analytics, knowledge engineering and scientific informatics solutions across the company’s drug discovery & development pipeline for a variety of therapeutic areas including oncology, diabetes, cardiovascular, neuroscience and infectious diseases.

Prior to AstraZeneca, Turpaz worked at Eli Lilly’s Singapore Centre for Drug Discovery as Director of Integrative Computational Sciences and at Affymetrix, Inc. Turpaz has BS in Biology from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School of Business. He also held an adjunct assistant professor at the Centre for Quantitative Medicine of Duke-National University of Singapore, Graduate Medical School in Singapore.

Kristina Peterson, MBA ‘90
Mayflower Partners

Rong Xu, MBA ‘10
Senior Marketing Manager
Boston Scientific Neuromodulation

Event Contact
Kristina Peterson MBA '90
Staff Liaison
Cassie Llewellyn-Smith